In vitro-in vivo correlations of scalable plga-risperidone implants for the treatment of schizophrenia

Pharmaceutical Research

Volumn 27, Issue 8, 2010, Pages 1730-1737

  Amann, Laura C ^a   Gandal, Michael J ^a,b   Lin, Robert ^a   Liang, Yuling ^a   Siegel, Steven J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

implant; in vitro in vivo correlation; PLGA; risperidone; schizophrenia

Indexed keywords

POLYGLACTIN; RISPERIDONE; LACTIC ACID; NEUROLEPTIC AGENT; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG IMPLANT; DRUG RELEASE; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; ANIMAL MODEL; BIODEGRADABLE IMPLANT; DRUG DELIVERY SYSTEM; HUMAN; SPRAGUE DAWLEY RAT;

ABSORBABLE IMPLANTS; ANIMALS; ANTIPSYCHOTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LACTIC ACID; MALE; MODELS, ANIMAL; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE; SCHIZOPHRENIA;

EID: 77955448039     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0152-4     Document Type: Article

References (39)

1. Siegel SJ, Dankert M, Phillips JM. Psychosis and schizophrenia (chapter 55). In: Waldman S, Terzic A, editors. Pharmacology and therapeutics: principles to practice. Philadelphia: Elsevier; 2008.
2. EQ Wu, et al. 2005 The economic burden of schizophrenia in the United States in 2002 J Clin Psychiatry 66 9 1122 1129 10.4088/JCP.v66n0906 16187769
3. DP Rice 1999 The economic impact of schizophrenia J Clin Psychiatry 60 Suppl 1 4 6 10037163 discussion 28-30
4. WH Crown, et al. 2001 Hospitalization and total medical costs for privately insured persons with schizophrenia Adm Policy Ment Health 28 5 335 351 10.1023/A:1011139215761 11678067 (Pubitemid 32912265)
5. JM Kane 2006 Utilization of long-acting antipsychotic medication in patient care CNS Spectr 11 12 Suppl 14 1 7 17146411 quiz 7-8
6. JA Lieberman, et al. 2005 Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 12 1209 1223 10.1056/NEJMoa051688 16172203 (Pubitemid 41345943)
7. TP Gilmer, et al. 2004 Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia Am J Psychiatry 161 4 692 699 10.1176/appi.ajp.161.4.692 15056516 (Pubitemid 38445514)
8. D Robinson, et al. 1999 Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder Arch Gen Psychiatry 56 3 241 247 10.1001/archpsyc.56.3.241 10078501 (Pubitemid 29125132)
9. PJ Weiden M Olfson 1995 Cost of relapse in schizophrenia Schizophr Bull 21 3 419 429 7481573
10. NR Schooler 2003 Relapse and rehospitalization: comparing oral and depot antipsychotics J Clin Psychiatry 64 Suppl 16 14 17 14680414
11. K Melkersson 2005 Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients J Clin Psychiatry 66 6 761 767 10.4088/JCP.v66n0614 15960571
12. KI Melkersson AL Hulting KE Brismar 2000 Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses J Clin Psychiatry 61 10 742 749 11078035
13. T Ozcanli, et al. 2006 Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity Prog Neuropsychopharmacol Biol Psychiatry 30 6 1163 1166 10.1016/j.pnpbp.2006.03.014 16632162 (Pubitemid 43949429)
14. F Benazzi 1998 Risperidone-induced hepatotoxicity Pharmacopsychiatry 31 6 241 10.1055/s-2007-979337 9930641
15. KG Yadalam GM Simpson 1988 Changing from oral to depot fluphenazine J Clin Psychiatry 49 9 346 348 3417620
16. C Rabin, et al. 2008 In vitro and in vivo demonstration of risperidone implants in mice Schizophr Res 98 1-3 66 78 10.1016/j.schres.2007.08.003 17765477 (Pubitemid 350235885)
17. SJ Siegel, et al. 2002 Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia Neuropsychopharmacology 26 6 817 823 10.1016/S0893-133X(01)00426-2 12007752 (Pubitemid 34455034)
18. JP Kitchell DL Wise 1985 Poly(lactic/glycolic acid) biodegradable drug-polymer matrix systems Methods Enzymol 112 436 448 10.1016/S0076-6879(85) 12034-3 4046859
19. JM Schakenraad, et al. 1989 In vivo and in vitro degradation of glycine/DL-lactic acid copolymers J Biomed Mater Res 23 11 1271 1288 10.1002/jbm.820231105 2606921
20. AC Sharon DL Wise 1981 Development of drug delivery systems for use in treatment of narcotic addiction NIDA Res Monogr 28 194 213 6791005
21. BA Sabel, et al. 1990 Levodopa delivery from controlled-release polymer matrix: delivery of more than 600 days in vitro and 225 days of elevated plasma levels after subcutaneous implantation in rats J Pharmacol Exp Ther 255 2 914 922 2243358
22. H Okada H Toguchi 1995 Biodegradable microspheres in drug delivery Crit Rev Ther Drug Carrier Syst 12 1 1 99 8521523
23. PA Janssen, et al. 1988 Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties J Pharmacol Exp Ther 244 2 685 693 2450200
24. JM Davis N Chen ID Glick 2003 A meta-analysis of the efficacy of second-generation antipsychotics Arch Gen Psychiatry 60 6 553 564 10.1001/archpsyc.60.6.553 12796218 (Pubitemid 36682312)
25. HA Nasrallah 2007 The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial J Clin Psychiatry 68 Suppl 1 5 11 17286522
26. CS Brown, et al. 1999 Atypical antipsychotics: Part II: adverse effects, drug interactions, and costs Ann Pharmacother 33 2 210 217 10.1345/aph.17216 10084417 (Pubitemid 29109684)
27. SS Iyer WH Barr HT Karnes 2006 Profiling in vitro drug release from subcutaneous implants: a review of current status and potential implications on drug product development Biopharm Drug Dispos 27 4 157 170 10.1002/bdd.493 16416503 (Pubitemid 43797112)
28. GL Amidon, et al. 1995 A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm Res 12 3 413 420 10.1023/A:1016212804288 7617530
29. United States Pharmacopeial Convention. The United States pharmacopeia. The national formulary, United States Pharmacopeial Convention: Rockville, Md., p. v.
30. SR Marder RC Meibach 1994 Risperidone in the treatment of schizophrenia Am J Psychiatry 151 6 825 835 7514366
31. DV Naiker, et al. 2006 Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat Eur J Pharmacol 540 1-3 87 90 10.1016/j.ejphar.2006.04.048 16730699 (Pubitemid 43866708)
32. FI Tarazi K Zhang RJ Baldessarini 2001 Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment J Pharmacol Exp Ther 297 2 711 717 11303062
33. T Moran-Gates, et al. 2007 Effects of risperidone on dopamine receptor subtypes in developing rat brain Eur Neuropsychopharmacol 17 6-7 448 455 10.1016/j.euroneuro.2006.10.004 17175142 (Pubitemid 46497655)
34. KL Metzger, et al. 2007 Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits Psychopharmacology (Berl) 190 2 201 211 10.1007/s00213-006-0616-8 (Pubitemid 46011180)
35. SJ Siegel, et al. 2006 Effect of drug type on the degradation rate of PLGA matrices Eur J Pharm Biopharm 64 3 287 293 10.1016/j.ejpb.2006.06.009 16949804 (Pubitemid 44585214)
36. E Rinaki A Dokoumetzidis P Macheras 2003 The mean dissolution time depends on the dose/solubility ratio Pharm Res 20 3 406 408 10.1023/A: 1022652004114 12669960 (Pubitemid 36288369)
37. TB Halene, et al. 2009 Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia Genes Brain Behav 8 661 675 10.1111/j.1601-183X.2009.00504.x 19563516
38. X Huang BL Chestang CS Brazel 2002 Minimization of initial burst in poly(vinyl alcohol) hydrogels by surface extraction and surface-preferential crosslinking Int J Pharm 248 1-2 183 192 10.1016/S0378-5173(02)00433-7 12429472 (Pubitemid 35341422)
39. X Huang CS Brazel 2001 On the importance and mechanisms of burst release in matrix-controlled drug delivery systems J Control Release 73 2-3 121 136 10.1016/S0168-3659(01)00248-6 11516493 (Pubitemid 32539245)